These effects, together with a former report demonstrating that a small-molecule ACKR3 agonist CCX771 reveals anxiolytic-like actions in mice,2 assist the strategy of concentrating on ACKR3 as a unique solution to modulate the opioid program, which could open new therapeutic avenues for opioid-r